Christopher A. Barker, MD, of Memorial Sloan Kettering Cancer Center, reviews the results of the RAMPART study, a phase II, multicenter, single-arm clinical trial evaluating response-adapted definitive radiotherapy in combination with cemiplimab-rwlc for locally advanced, unresectable cutaneous squamous cell carcinoma (CSCC) (Abstract 9506).
Asaf Maoz, MD, of Dana-Farber Cancer Institute, Mass General Brigham, and Harvard Medical School, talks about whether prospective assessment of CA 19-9 has utility as part of pancreatic cancer surveillance among high-risk individuals (Abstract 10527).
Peter Schmid, MD, PhD, FRCP, of Queen Mary University of London, shares more data from the phase III lidERA BC clinical trial. This analysis focused on the efficacy and safety of giredestrant in patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer, looking at both premenopausal and postmenopausal populations (Abstract 502).
Dor Abelman, BS, of the University of Toronto, reviews results of a comparison of two minimally invasive measurable residual disease (MRD) assays—BM-informed cfDNA whole-genome sequencing (cfWGS) and plasma proteomic MRD (EasyM)—in patients with multiple myeloma (Abstract 7546).
Jason R. Westin, MD, FASCO, of The University of Texas MD Anderson Cancer Center, provides an update on the safety and efficacy data from the phase III SUNMO trial, which compared mosunetuzumab and polatuzumab vedotin vs rituximab, gemcitabine, and oxaliplatin in patients with relapsed or refractory large B-cell lymphoma (LBCL) (Abstract 7007).
Alicia K. Morgans, MD, FASCO, of Dana-Farber Cancer Institute, discusses data from the phase II ARACOG (AFT-47) randomized clinical trial, which compared the two androgen receptor pathway inhibitors’ effects on cognitive function in patients with advanced prostate cancer (Abstract 5005).
